Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fruquintinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 17/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 4/20 | 0.54 |
| ▸ | AURKA | O14965 | 3/20 | 0.54 |
| ▸ | TEK | Q02763 | 3/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | KIF5B | P33176 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fruquintinib SCHEMBL947183 | 1.00 | KDR (1.00) | KDRFLT1FLT4METAURKA | |
| Fruquintinib SCHEMBL29366206 | 1.00 | KDR (1.00) | KDRFLT1FLT4METAURKA | |
| SCHEMBL12909830 | 0.93 | KDR (0.87) | KDRFLT1FLT4METAURKA | |
| SCHEMBL945594 | 0.91 | KDR (0.83) | KDRFLT1FLT4METAURKA | |
| SCHEMBL11931698 | 0.91 | KDR (0.83) | KDRFLT1FLT4METAURKA | |
| SCHEMBL11931690 | 0.90 | KDR (0.81) | KDRFLT1FLT4METAURKA | |
| SCHEMBL30753475 | 0.89 | KDR (0.79) | KDRFLT1FLT4 | |
| SCHEMBL30753458 | 0.89 | KDR (0.79) | KDRFLT1FLT4 | |
| SCHEMBL30753470 | 0.89 | KDR (0.79) | KDRFLT1FLT4 | |
| SCHEMBL943909 | 0.88 | KDR (0.79) | KDRFLT1FLT4METAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117487912-A | Tumor prognosis evaluation marker for tyrosine kinase inhibitor treatment | 复旦大学附属肿瘤医院 | 2024-02-02 | — | — | CN | claimed |
| US-12624009-B2 | Hydrate of VEGFR inhibitor, crystal form thereof and preparation method therefor | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD (CN) | 2026-05-12 | — | — | US | disclosed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250388552-A1 | HYDRATE OF VEGFR INHIBITOR, CRYSTAL FORM THEREOF AND PREPARATION METHOD THEREFOR | CHENGDU EASTON BIOPHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| EP-4637821-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Actinium Pharmaceuticals, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250205375-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | ACTINIUM PHARMACEUTICALS, INC. | 2025-06-26 | — | — | US | disclosed |
| CN-120051468-A | Hydrate of VEGFR inhibitor, crystal form thereof and preparation method thereof | 成都苑东生物制药股份有限公司 | 2025-05-27 | — | — | CN | disclosed |
| WO-2025100428-A1 | COMBINATION OF ANTI-CD147 ANTIBODY AND ANOTHER ANTITUMOR AGENT | 第一三共株式会社 | 2025-05-15 | — | — | WO | disclosed |
| EP-4153775-B1 | SIMULTANEOUS SPATIO-TEMPORAL MEASUREMENT OF GENE EXPRESSION AND CELLULAR ACTIVITY | 10X GENOMICS INC (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2024138019-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240110228-A1 | SIMULTANEOUS SPATIO-TEMPORAL MEASUREMENT OF GENE EXPRESSION AND CELLULAR ACTIVITY | 10X GENOMICS, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11866767-B2 | Simultaneous spatio-temporal measurement of gene expression and cellular activity | 10X GENOMICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| CN-114751858-B | Quinolinyl-containing tranexamic acid derivative and preparation and application thereof | 沈阳药科大学 | 2023-09-12 | — | — | CN | disclosed |
| US-20230265489-A1 | SIMULTANEOUS SPATIO-TEMPORAL MEASUREMENT OF GENE EXPRESSION AND CELLULAR ACTIVITY | 10X GENOMICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11624086-B2 | Simultaneous spatio-temporal measurement of gene expression and cellular activity | 10X GENOMICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| EP-4153775-A1 | SIMULTANEOUS SPATIO-TEMPORAL MEASUREMENT OF GENE EXPRESSION AND CELLULAR ACTIVITY | 10X Genomics, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| WO-2022087018-A1 | IMPROVED FLUOROURACIL-BASED MULTI-AGENT CHEMOTHERAPY FOR TREATMENT OF METASTATIC COLORECTAL CANCER | G1 THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220090175-A1 | SIMULTANEOUS SPATIO-TEMPORAL MEASUREMENT OF GENE EXPRESSION AND CELLULAR ACTIVITY | 10X GENOMICS, INC. | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | KDR 328/4885FLT1 160/4885FLT4 392/4885 |
| US-20250388552-A1 | HYDRATE OF VEGFR INHIBITOR, CRYSTAL FORM THEREOF AND PREPARATION METHOD THEREFOR | FLT1, FLT4, KDR | KDR 3/4885FLT1 1/4885FLT4 2/4885 |
| US-12624009-B2 | Hydrate of VEGFR inhibitor, crystal form thereof and preparation method therefor | FLT1, KDR, FLT4 | KDR 2/4885FLT1 1/4885FLT4 3/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | KDR 4542/4885FLT1 4870/4885FLT4 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.